2026年11月1日-6日，全球医药市场共签署了24项资产授权和合作协议。中国市场共达成7项交易，包括6项出海交易和1项国内交易。
中国市场，本周最大的交易是中国生物制药与Boehringer Ingelheim就包括ADC和TCE在内的多个项目达成选择权与许可协议，首付款3.58亿美元，总金额可达70亿美元。
中国以外市场，本周共签署了17项资产授权和合作协议。最大的交易是Abbvie与Nxera就新型EP4受体激动剂NXE0033744签订独家全球许可协议，首付款1亿美元，潜在开发和商业里程碑13.7亿美元，以及分层特许权使用费。
From November 1 to 6, a total of 24 biopharmaceutical licensing and collaboration transactions were announced globally. Of these, 7 were China-related, defined as transactions involving at least one China-based company. These comprised six out-licensing deals and one domestic partnership.
In China, the largest transaction involved Sino Biopharmaceutical and Boehringer Ingelheim, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), with an upfront payment of $358 million and a total deal value of $7 billion.
Outside China, 17 deals were announced. The largest transaction involved Nxera Pharma and AbbVie for NXE0033744, a novel EP4 receptor agonist, with an upfront payment of $100 million and $1.37 billion in development and commercial milestone payments, plus tiered royalties.
3. M&A Deals
4. Top Deals of 2026
